Biosimilars: Patient and physician acceptability is the fifth hurdle to market competition

Alan Lyles

Research output: Contribution to journalLetter

Abstract

Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.

Original languageEnglish (US)
Pages (from-to)6-7
Number of pages2
JournalGaBI Journal
Volume4
Issue number1
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Biosimilar Pharmaceuticals
Marketing
Physicians

Keywords

  • Acceptability
  • Biologicals
  • Biosimilars
  • Interchangeability
  • Pricing

ASJC Scopus subject areas

  • Pharmacy
  • Drug guides

Cite this

Biosimilars : Patient and physician acceptability is the fifth hurdle to market competition. / Lyles, Alan.

In: GaBI Journal, Vol. 4, No. 1, 2015, p. 6-7.

Research output: Contribution to journalLetter

@article{049e25d9d06f4d6297f85857383028cb,
title = "Biosimilars: Patient and physician acceptability is the fifth hurdle to market competition",
abstract = "Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.",
keywords = "Acceptability, Biologicals, Biosimilars, Interchangeability, Pricing",
author = "Alan Lyles",
year = "2015",
doi = "10.5639/gabij.2015.0401.002",
language = "English (US)",
volume = "4",
pages = "6--7",
journal = "GaBI Journal",
issn = "2033-6403",
publisher = "Pro Pharma Communications International",
number = "1",

}

TY - JOUR

T1 - Biosimilars

T2 - Patient and physician acceptability is the fifth hurdle to market competition

AU - Lyles, Alan

PY - 2015

Y1 - 2015

N2 - Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.

AB - Biosimilar products confront novel market authorization and post-marketing use hurdles. Existing evidence is insufficient to fully address physician and payer acceptability thresholds.

KW - Acceptability

KW - Biologicals

KW - Biosimilars

KW - Interchangeability

KW - Pricing

UR - http://www.scopus.com/inward/record.url?scp=85008257140&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008257140&partnerID=8YFLogxK

U2 - 10.5639/gabij.2015.0401.002

DO - 10.5639/gabij.2015.0401.002

M3 - Letter

AN - SCOPUS:85008257140

VL - 4

SP - 6

EP - 7

JO - GaBI Journal

JF - GaBI Journal

SN - 2033-6403

IS - 1

ER -